| David Craft, MD | |
|
1200 Manor Dr, Chalfont, PA 18914-2282 | |
| (800) 321-9999 | |
| (267) 479-1321 |
| Full Name | David Craft |
|---|---|
| Gender | Male |
| Speciality | Orthopedic Surgery |
| Experience | 36 Years |
| Location | 1200 Manor Dr, Chalfont, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1376526475 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Jefferson Health Home Care And Hospice | Willow grove, PA | Home health agency |
| Abington Memorial Hospital | Abington, PA | Hospital |
| Abington Health Lansdale Hospital | Lansdale, PA | Hospital |
| Rothman Orthopaedic Specialty Hospital | Bensalem, PA | Hospital |
| Doylestown Hospital | Doylestown, PA | Hospital |
| Grand View Hospital | Sellersville, PA | Hospital |
| Willowbrooke Ctskdcarectr Atnormandy Farms Estates | Blue bell, PA | Nursing home |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Novacare Outpatient Rehabilitation East Inc | 3678480290 | 617 |
| Reconstructive Orthopaedic Associates Ii Llc | 7416845318 | 263 |
News Archive
Researchers from the University of Cincinnati (UC) have received a four-year, $3.7 million grant from the U.S. Department of Defense for investigations into circadian rhythms that could lead to enhanced understanding of disease treatments, trauma care and human combat performance.
Merck, known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration recently approved ISENTRESS for oral suspension, a new pediatric formulation of Merck's integrase inhibitor. With this approval, ISENTRESS is now indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in patients four weeks of age and older.
Anadys Pharmaceuticals, Inc. announced today that it has initiated the planned Phase IIb study of ANA598 in combination with pegylated interferon and ribavirin. The protocol for the study has been cleared by the United States Food and Drug Administration and Health Canada.
Immunotherapy with nivolumab and low-dose ipilimumab could become a new first line treatment in patients with some metastatic colorectal cancers following late-breaking results from the CheckMate-142 trial reported at the ESMO 2018 Congress in Munich.
Tianyin Pharmaceutical Inc., a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) announced financial results for second quarter of the fiscal year 2013.
› Verified 2 days ago
| Entity Name | Reconstructive Orthopaedic Associates Ii Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1861433278 PECOS PAC ID: 7416845318 Enrollment ID: O20040310000667 |
News Archive
Researchers from the University of Cincinnati (UC) have received a four-year, $3.7 million grant from the U.S. Department of Defense for investigations into circadian rhythms that could lead to enhanced understanding of disease treatments, trauma care and human combat performance.
Merck, known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration recently approved ISENTRESS for oral suspension, a new pediatric formulation of Merck's integrase inhibitor. With this approval, ISENTRESS is now indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in patients four weeks of age and older.
Anadys Pharmaceuticals, Inc. announced today that it has initiated the planned Phase IIb study of ANA598 in combination with pegylated interferon and ribavirin. The protocol for the study has been cleared by the United States Food and Drug Administration and Health Canada.
Immunotherapy with nivolumab and low-dose ipilimumab could become a new first line treatment in patients with some metastatic colorectal cancers following late-breaking results from the CheckMate-142 trial reported at the ESMO 2018 Congress in Munich.
Tianyin Pharmaceutical Inc., a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) announced financial results for second quarter of the fiscal year 2013.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| David Craft, MD 833 Chestnut St Ste 520, Philadelphia, PA 19107-4430 Ph: (672) 339-3558 | David Craft, MD 1200 Manor Dr, Chalfont, PA 18914-2282 Ph: (800) 321-9999 |
News Archive
Researchers from the University of Cincinnati (UC) have received a four-year, $3.7 million grant from the U.S. Department of Defense for investigations into circadian rhythms that could lead to enhanced understanding of disease treatments, trauma care and human combat performance.
Merck, known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration recently approved ISENTRESS for oral suspension, a new pediatric formulation of Merck's integrase inhibitor. With this approval, ISENTRESS is now indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in patients four weeks of age and older.
Anadys Pharmaceuticals, Inc. announced today that it has initiated the planned Phase IIb study of ANA598 in combination with pegylated interferon and ribavirin. The protocol for the study has been cleared by the United States Food and Drug Administration and Health Canada.
Immunotherapy with nivolumab and low-dose ipilimumab could become a new first line treatment in patients with some metastatic colorectal cancers following late-breaking results from the CheckMate-142 trial reported at the ESMO 2018 Congress in Munich.
Tianyin Pharmaceutical Inc., a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) announced financial results for second quarter of the fiscal year 2013.
› Verified 2 days ago
Gregory G Gallant, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 1200 Manor Dr, Chalfont, PA 18914 Phone: 267-339-3558 Fax: 267-339-3763 | |
Guy Lee, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 1200 Manor Dr, Chalfont, PA 18914 Phone: 267-339-3558 Fax: 267-339-3763 | |
T Robert Takei, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 1200 Manor Dr, Chalfont, PA 18914 Phone: 267-339-3558 Fax: 267-339-3763 | |
Victor W Hsu, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 1200 Manor Dr, Chalfont, PA 18914 Phone: 267-339-3558 Fax: 267-336-3763 | |
Dr. Thomas Edward Greene, M.D Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 1200 Manor Dr, Chalfont, PA 18914 Phone: 267-339-3558 Fax: 267-339-3763 |